Wall Street's Growing Optimism Toward Abbott Laboratories
Abbott Laboratories (NYSE: ABT) is gaining renewed attention from Wall Street analysts due to its strong earnings growth and expanding Medical Devices segment. In Q2 2026, the company reported a 13% sales increase to $12.6 billion with adjusted EPS rising to $1.31. Analysts have upgraded their ratings and price targets for Abbott, reflecting confidence in its future performance. The Medical Devices division is central to this optimism, growing at an impressive rate of 8.4%. This segment includes strong performers like electrophysiology products and diabetes monitoring solutions such as Libre Duo. Additionally, the recent acquisition of Exact Sciences has expanded Abbott's presence in cancer diagnostics, adding long-term growth potential. Despite its solid performance, challenges remain for Abbott due to slower-growth segments and a high valuation at 33 times earnings. However, analysts believe that continued momentum from Medical Devices and new product launches could support both earnings and dividend increases.
Topics: analyst upgrades dividend growth earnings report medical devices